MedTrace Logo

Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries

NCT04198571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2024-03-26

Study results available
· View outcomes & findings →

Summary

MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated with Zinforo® (ceftaroline fosamil) in a Usual Care Setting

Conditions

  • Community Acquired Pneumonia
  • Complicated Skin and Soft Tissue Infection

Interventions

DRUG

Zinforo (ceftaroline fosamil)

IV Solution

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-17
Primary Completion
2021-07-23
Completion
2021-08-30
FDA Drug
Yes

Countries

  • Brazil
  • Colombia
  • France
  • Greece
  • Italy
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04198571 on ClinicalTrials.gov